Contract Deobligations Alert — February 03, 2026

Two firm-fixed price contracts totaling $457M fully obligated through 2028 for border LPOE and NIH lab expansion, with 23% average outlay indicating steady execution.

$366M combined obligations with 71% average outlay, extending to 2027+ for CMS Marketplace support and NIAID data coordination.

Large HHS award for BIOMAP drug production with minimal 4% outlay, signaling federal health R&D commitment but limited private upside.

Low outlays average 37% of obligations (e.g., $11M/$304M, $21M/$277M), signaling potential ramp delays or deobligation triggers.

Long tenors to 2028 expose to federal budget shifts, especially HHS-dependent contracts (80% of total).

Firm-fixed price (Hensel Phelps $457M) risks cost overruns; cost-plus structures limit margins via audits.

$192M+ in unexercised options (e.g., $72M BARDA, $117M Emmes, $2M GD) could boost values 15-70%.

NIH/GSA lab and border infrastructure wins position for follow-ons in health/construction ($638M combined).

80% of $1.1B in HHS contracts for labs, data services, and drug production, with high outlays signaling execution momentum.

$457M Hensel Phelps awards fully obligated for federal buildings/labs under full competition.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"41% of total value across two bullish awards with $178M remaining outlays.", "trigger"=>"Outlay acceleration >20% QoQ or new GSA/NIH awards"}

{"entity"=>"HHS Budget Allocations", "reason"=>"Dominates 4/5 records; deobligations may signal cuts.", "trigger"=>"FY2027 cuts >10% to R&D/construction lines"}

{"entity"=>"General Dynamics IT", "reason"=>"$196M CMS order at 51% outlay with $2M options upside.", "trigger"=>"Extension to 2027 or subaward delays"}